First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(30 sites)

United States

GSK Investigational Site, Miami, Florida

GSK Investigational Site, Boston, Massachusetts

GSK Investigational Site, St Louis, Missouri

GSK Investigational Site, New York, New York

GSK Investigational Site, Portland, Oregon

GSK Investigational Site, Philadelphia, Pennsylvania

GSK Investigational Site, Houston, Texas

Belgium

GSK Investigational Site, Leuven

China

GSK Investigational Site, Beijing

GSK Investigational Site, Guangzhou

GSK Investigational Site, Wuhan

France

GSK Investigational Site, Bordeaux

GSK Investigational Site, Lyon

GSK Investigational Site, Marseille

GSK Investigational Site, Villejuif

Germany

GSK Investigational Site, Berlin

GSK Investigational Site, Essen

Italy

GSK Investigational Site, Milan

Japan

GSK Investigational Site, Chiba

GSK Investigational Site, Tokyo

Netherlands

GSK Investigational Site, Amsterdam

GSK Investigational Site, Rotterdam

South Korea

GSK Investigational Site, Seongnam-si Gyeonggi-do

GSK Investigational Site, Seoul

Spain

GSK Investigational Site, Barcelona

United Kingdom

GSK Investigational Site, Leeds

GSK Investigational Site, London